At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LXRX Lexicon Pharmaceuticals
Pre-Mkt 05-06 04:43:48 EDT
1.65
+0.05
+3.13%
High1.65Low1.57Vol1.59M
Open1.60D1 Closing1.60Amplitude5.31%
Mkt Cap699.07MTradable Cap689.70MTotal Shares423.68M
T/O2.54MT/O Rate0.38%Tradable Shares418.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Lexicon Pharmaceuticals Inc expected to post a loss of 3 cents a share - Earnings Preview
Reuters  ·  05-05 20:32
Lexicon Pharmaceuticals Inc expected to post a loss of 3 cents a share - Earnings Preview
Lexicon Pharmaceuticals : Loan Facility Provides for an Initial Interest-Only Period of 18 Months, With Potential for Two Six-Month Extensions
THOMSON REUTERS  ·  05-05 04:05
Lexicon Pharmaceuticals : Loan Facility Provides for an Initial Interest-Only Period of 18 Months, With Potential for Two Six-Month Extensions
Lexicon Pharmaceuticals Announces $100 Million Loan Facility With Hercules Capital
THOMSON REUTERS  ·  05-05 04:05
Lexicon Pharmaceuticals Announces $100 Million Loan Facility With Hercules Capital
Lexicon Pharmaceuticals: Under Terms, Initial $55 Mln Tranche Will Be Used to Repay Existing Loan Facility With Oxford Finance
THOMSON REUTERS  ·  05-05 04:05
Lexicon Pharmaceuticals: Under Terms, Initial $55 Mln Tranche Will Be Used to Repay Existing Loan Facility With Oxford Finance
Press Release: Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
Dow Jones  ·  05-05 04:05
Press Release: Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
Lexicon Pharmaceuticals shareholders approved increase in authorized common shares to 900 million
Reuters  ·  05-01
Lexicon Pharmaceuticals shareholders approved increase in authorized common shares to 900 million
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
GlobeNewswire  ·  04-30
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Lexicon says Phase 2b data support pilavapadin 10 mg for Phase 3 DPNP trial
Reuters  ·  04-17
Lexicon says Phase 2b data support pilavapadin 10 mg for Phase 3 DPNP trial
Lexicon to present Phase 3 SCORED and SOTA-P-CARDIA sotagliflozin data at ACC 2026
Reuters  ·  03-24
Lexicon to present Phase 3 SCORED and SOTA-P-CARDIA sotagliflozin data at ACC 2026
Lexicon Pharma Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones  ·  03-23
Lexicon Pharma Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lexicon Pharmaceuticals (LXRX)
TIPRANKS  ·  03-23
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lexicon Pharmaceuticals (LXRX)
Lexicon, Novo Nordisk announce initiation of LX9851 study
TIPRANKS  ·  03-23
Lexicon, Novo Nordisk announce initiation of LX9851 study
Novo Nordisk initiates Phase 1 trial of Lexicon-licensed obesity candidate LX9851
Reuters  ·  03-23
Novo Nordisk initiates Phase 1 trial of Lexicon-licensed obesity candidate LX9851
Lexicon Pharmaceuticals Inc - Phase 1 Study of Lx9851 Expected to Complete in Q1 2027
THOMSON REUTERS  ·  03-23
Lexicon Pharmaceuticals Inc - Phase 1 Study of Lx9851 Expected to Complete in Q1 2027
Lexicon Pharmaceuticals and Novo Nordisk Announce Initiation of Phase 1 Study With Oral Obesity Drug Candidate Lx9851
THOMSON REUTERS  ·  03-23
Lexicon Pharmaceuticals and Novo Nordisk Announce Initiation of Phase 1 Study With Oral Obesity Drug Candidate Lx9851
Lexicon Pharmaceuticals Inc - Earns Second $10 Mln Milestone; Eligible for up to $1 Bln in Payments
THOMSON REUTERS  ·  03-23
Lexicon Pharmaceuticals Inc - Earns Second $10 Mln Milestone; Eligible for up to $1 Bln in Payments
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK)
TIPRANKS  ·  03-13
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK)
Lexicon announces results from post hoc analysis on data of sotagliflozin
TIPRANKS  ·  03-11
Lexicon announces results from post hoc analysis on data of sotagliflozin
Lexicon to present sotagliflozin kidney function analysis at ATTD conference
Reuters  ·  03-11
Lexicon to present sotagliflozin kidney function analysis at ATTD conference
Lexicon Pharma Is Maintained at Buy by Citigroup
Dow Jones  ·  03-10
Lexicon Pharma Is Maintained at Buy by Citigroup

Introduction

Company Name.
Lexicon Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Issue price:
--